Pay in 4 interest-free payments of $7.14 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
launch pending approval Zepbound Kwikpen regulatory action Lilly Q1 2026 earnings (early May) Novo Q1 2026 earnings (early May, watch for any GLP-1 psychiatric trial announcements) Q3 and Q4 2026 Retatrutide TRIUMPH-1, TRIUMPH-2, TRIUMPH-3 topline readouts (obesity, OSA) Retatrutide TRANSCEND-T2D readouts (diabetes) Orforglipron ACHIEVE-4 Phase 3 T2D readout Brenipatide for MDD Phase 3 trial initiation Eloralintide Phase 3 initiation 2027 Expected earliest topline results for brenipatide Phase 3 in alcohol use disorder Expected earliest topline results for brenipatide Phase 3 in bipolar disorder Possible regulatory submissions for retatrutide in lead obesity indications Lilly R&D Day announcements expanding the brenipatide program to additional indications (likely) 2028 Earliest realistic FDA decision on brenipatide for AUD assuming successful Phase 3 Phase 2 readouts for brenipatide in smoking, opioid use disorder, and asthma None of these dates are guaranteed
If prescribed an affordable compounded weight loss medication, you'll receive a customized holistic plan tailored just for you and your goals
The Phase 2b protocol used one dose per day for 12 weeks
PlexusDx compounded semaglutide injections support flexible micro-dosing options that standard manufacturers don't offer, enabling personalized adjustment schedules matched to your tolerance
Glutathione: A key frontier of heavy-metal detoxification and tolerance in plants Abstract Heavy metal (HMs) toxicity is one of the major critical threats to agricultural plant production and global food security
Van Loo J, Coussement P, De Leenheer L, Hoebregs H, Smits G
US$ 29.10
US$ 25.43
US$ 23.35
